- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03640403
Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania (InSMART-school)
Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A Controlled Randomised Trial
Background:
In high-transmission settings, up to 70% of school-aged children harbour malaria parasites which is mostly asymptomatic, thus, from an epidemiological point of view, they contribute significantly as reservoir to onward malaria transmission to others. In endemic areas, malaria accounts for around 50% of the mortality, 13-50% of all school absenteeism, and causes anaemia in approximately 85 million school-aged children of sub Saharan Africa that also impairs the cognitive development of children. Intermittent preventive treatment (IPT) of pregnant women as well as seasonal malaria chemoprevention in children under the age of five have been implemented in several sub-Saharan countries and have proven to be very effective. However, none of these IPT strategies is targeting school children. A clinical trial is being conducted to expand the IPT by testing effectiveness and safety of two antimalarial drugs Dihydroartemisinin-piperaquine (DP) and Artesunate-amodiaquine (ASAQ) in preventing malaria related morbidity in school aged children (IPTsc) living in high endemic areas.
Methods:
A randomized, open label, controlled trial will enrol 1602 school children aged 5-15 years, who will receive either DP or ASAQ or control (no drug ), using a "balanced block design" with the "standard of care" arm as reference. The interventional treatments are given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects. All study-arms receive bed nets, early diagnosis and care for malaria, and praziquantel and albendazole as mass treatment for helminthiasis. The primary endpoint are change from baseline in mean haemoglobin concentration at months 12 and 20 of follow-up and clinical malaria incidence from month 0 till months 12 and 20 of follow up. Adverse events will be monitored throughout the study. Mixed design methods will be used to assess the acceptability, cost-effectiveness and feasibility of this IPTsc as part of a more comprehensive school children health package.
Discussion:
The national school health programme (NSHP), Tanzania, combines schistosomiasis and soil transmitted helminthes (STH) control package under national schistosomiasis and STH control programme (NSSCP). Malaria intervention using IPTsc strategy may be integrated in NSHP with the same platform as NSSCP, however, there is limited systematic evidence to assess the operational feasibility of this approach. School aged children are a reachable target population in any endemic malaria setting. The suggested strategy will provide effective protection against malaria, hasten either the elimination process and/or diminish the reservoir and burden.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Tanga, Tanzania, 255
- National Institute for Medical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Includes parental/guardian informed consent
- Assent by primary school children aged 11 years and above.
- Aged 5-15 years.
- Currently, lives within the pre-defined catchment area of Muheza District.
- Will remain within the same area throughout the study period (preferably class five and below).
Exclusion Criteria:
- Students at class 6 and 7
- Currently enrolled in another study or participated in another investigational drug study within the last 30 days.
- Known to have heart disease or a known cardiac ailment.
- Reports known hypersensitivity to the study drugs.
- Not willing to undergo all study procedures including physical examination and to provide blood samples as per this study protocol.
- Having clinical features of severe anaemia
- Febrile due to non-malaria illness at the time of recruitment.
- Has apparent severe infection or any condition that requires hospitalization
- Illness or conditions like hematologic, cardiac, renal, hepatic diseases which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study, including known G6PD deficiency and SS sickle cell.
- Body weight < 14 k
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: DP
Dihydroartemisinin-piperaquine (DP), antimalarial drug to be given every 4 months 3 rounds for the first year.
A second non-interventional year will assess possible rebound effects.
|
Dihydroartemisinin-piperaquine (DP).
One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria.
It will to be given every 4 months 3 rounds for a year.
|
ACTIVE_COMPARATOR: ASAQ
Artesunate-amodiaquine (ASAQ), antimalarial drugs to be given every 4 months 3 rounds for the first year.
A second non-interventional year will assess possible rebound effects.
|
Artesunate-amodiaquine (ASAQ).
One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria.
It will to be given every 4 months 3 rounds for a year.
|
NO_INTERVENTION: Control
No intervention drugs will be given, but normal routine standard of care will be provided.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in mean haemoglobin concentration at months 12 and 20 of follow-up
Time Frame: at months 0, 12 and 20
|
Will measure change from baseline haemoglobin concentration at month 12 (intervention period) and at month 20 (post intervention period to assess rebound effect) [Note: a trend of change at each visit will also be assessed with respect to malaria seasonality]
|
at months 0, 12 and 20
|
Clinical malaria incidence from month 0 till months 12 and 20 of follow up
Time Frame: at months 0, 12 and 20
|
number of symptomatic malaria episodes during and after intervention period
|
at months 0, 12 and 20
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of asymptomatic malaria infections at month 0, 12 and 20 of follow up
Time Frame: from month 0 till month12 and 20
|
to be measured from microscopic detection of malaria parasite on blood slides
|
from month 0 till month12 and 20
|
Prevalence of PCR confirmed sub-microscopic parasitaemia at months 0,12 and 20 of follow up
Time Frame: at months 0, 12 and 20
|
Polymerase chain reaction (PCR) confirmed from random subset of finger prick dry blood spots samples
|
at months 0, 12 and 20
|
Prevalence of soil transmitted helminths and schistosomiasis
Time Frame: at baseline, at month 12 and month 20.
|
A stool sample will be used to determine prevalence (defined as adult or eggs) of STH and S. mansoni infection determined by duplicate Kato-Katz thick smears technique.
Urine samples will be visually examined for the presence of blood (macrohaematuria) followed by laboratory examination for schistosomiasis infection (S.haematobium)
|
at baseline, at month 12 and month 20.
|
Prevalence of schistosomiasis
Time Frame: at baseline, at month 12 and month 20.
|
Urine samples will be visually examined for the presence of blood (macrohaematuria) followed by laboratory examination for schistosomiasis infection (S.haematobium) for confirmation.
|
at baseline, at month 12 and month 20.
|
Prevalence of validated common P. falciparum polymorphisms known to be associated with drug sensitivity at baseline, at months 12 and 20
Time Frame: at baseline, at month 12 and 20.
|
from random subset of finger prick dry blood spots samples
|
at baseline, at month 12 and 20.
|
Proportion of children seropositive for Plasmodium falciparum AMA-1 and MSP-119 at baseline, at month 12 and 20
Time Frame: at baseline, at month 12 and 20.
|
from random subset of finger prick dry blood spots samples, Antibody responses to P. falciparum blood-stages antigens, apical membrane antigen (AMA-1) and merozoite surface protein (MSP-119) will be determined.
|
at baseline, at month 12 and 20.
|
Change in serum antibody responses to Plasmodium falciparum AMA-1 and MSP-119 at baseline, at month 12 and 20
Time Frame: at baseline, at month 12 and 20.
|
From random subset of finger prick dry blood spots samples to be eluted for ELISA
|
at baseline, at month 12 and 20.
|
Percentages of school children with malnutrition through WHO's BMI z-score
Time Frame: at month 0, 12, and 20
|
weight in kilograms and height in meters will be combined to report BMI in kg/m^2
|
at month 0, 12, and 20
|
Relative risk (RR), for all adverse events categorised to severity at month 12 and 20
Time Frame: at month 12 and 20
|
Adverse events will be detected throughout the study, Each intervention arm will be compared to control arm to determine risk of an adverse event among the two arms.
Also events in two intervention arms will be compared to each other to assess risk in the two intervention arms.
|
at month 12 and 20
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of days missed school attendance pre and post intervention period
Time Frame: at baseline, at month 12 and 20
|
number of days absent from school pre and post intervention period
|
at baseline, at month 12 and 20
|
Change in educational performance
Time Frame: at baseline, at month 12 and 20
|
measured by annual change in average score of educational performance pre and post intervention period [to be provided by respective class teachers]
|
at baseline, at month 12 and 20
|
change in sustained attention on cognition evaluated using two code transmission tasks using TEA-Ch
Time Frame: evaluated at baseline, at month 12 and 20.
|
sub group of 20 students selected at random in each class will be involved, sustained attention will be evaluated using two code transmission tasks, adapted from the Test of Everyday Attention for Children (TEA-Ch)
|
evaluated at baseline, at month 12 and 20.
|
change in psychomotor functions tested by 20mShuttle Run Test pre and post intervention
Time Frame: evaluated at baseline, at month 12 and 20.
|
sub group of 20 students selected at random in each class will be involved.Physical fitness will also be assessed using the 20 meter Shuttle Run Test (20mSRT).
During this test children run continuously between two lines apart turning when signalled to do so by recorded beeps and a "shuttle" is defined as a run between one line to another.
The 20mSRT has 20 levels.
|
evaluated at baseline, at month 12 and 20.
|
Proportion of participants accepting IPTsc, using and completing dose of given study drugs.
Time Frame: at baseline, month 4, and 8
|
This will be useful on future pragmatic implementation
|
at baseline, month 4, and 8
|
Comparison of cost effectiveness of intervention between groups.
Time Frame: at month 12.
|
Evaluated by assessing the implementation cost (setup, salaries, transport, price scenarios, etc), the study impact as well as possible synergies with other school health intervention programs.
In addition,cost per child treated per year, the cost per anaemia case averted and cost per case P. falciparum parasitaemia averted as a result of the intervention, will also be evaluated to determine cost effectiveness of the program.
|
at month 12.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: John PA Lusingu, MD, PhD, National Institute for Medical Research, Tanzania
- Principal Investigator: Jean-pierre Van geertruyden, MD, PhD, Global health institute, University of Antwerp, Belgium.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Vector Borne Diseases
- Parasitic Diseases
- Protozoan Infections
- Malaria
- Malaria, Falciparum
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Anthelmintics
- Schistosomicides
- Antiplatyhelmintic Agents
- Artesunate
- Piperaquine
- Amodiaquine
- Artenimol
Other Study ID Numbers
- TEAM VERSION3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Cornell UniversityUniversity of California, Los AngelesCompletedPregnancy Anemia | Newborn; AnemiaUnited States
-
Peking Union Medical College HospitalRecruiting
Clinical Trials on Dihydroartemisinin-piperaquine
-
London School of Hygiene and Tropical MedicineMedical Research Council Unit, The GambiaTerminated
-
University of OxfordMahidol Oxford Tropical Medicine Research UnitCompleted
-
Indonesia UniversityCompleted
-
Liverpool School of Tropical MedicineThe Research Council of Norway; Makerere University; Kenya Medical Research InstituteCompleted
-
Richard MwaisweloNational Institute for Medical Research, Tanzania; Muhimbili University of... and other collaboratorsCompletedMalaria | Chemoprophylaxis | Underfive ChildrenTanzania
-
Menzies School of Health ResearchWorld Health Organization; Eijkman Institute for Molecular BiologyCompletedPlasmodium Falciparum Infection | Plasmodium Vivax InfectionIndonesia
-
University of California, San FranciscoMahidol University; Holley-Cotec Pharmaceuticals Co., LTD.Completed
-
National Institute for Medical Research, TanzaniaNational Malaria Control Program, TanzaniaActive, not recruiting
-
Centro de Investigação em Saúde de ManhiçaBarcelona Institute for Global HealthCompleted
-
London School of Hygiene and Tropical MedicineUniversity of Sheffield; Institute of Tropical Medicine, BelgiumCompleted